文 献10）Sung C, An J, Lee S, Park J, Lee KS, Kim I-H, et al. Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer. Nat Cancer 2023; 4: 844-59.11）Kim W, Cho YA, Min KH, Kim DC, Lee KE. Machine learning approaches for assessing risk factors of adrenal insufficiency in patients undergoing immune checkpoint inhibitor therapy. Pharmaceuticals 2023; 16: 1097.12）Gong L, Gong J, Sun X, Yu L, Liao B, Chen X, et al. Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning. Front Immunol 2023; 14: 1138489.13）Ashraf S, Saleem S, Ahmed T, Aslam Z, Muhammad D. Conversion of adverse data corpus to shrewd output using sampling metrics. Vis Comput Ind Biomed Art 2020; 3: 19.14）Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, et al. Factors associated with immune checkpoint inhibitor–related myocarditis. JAMA Oncol 2019; 5: 1635-7.15）Liu M, Cheng X, Ni R, Zheng B, Huang S, Yang J. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis. Front Immunol 2022; 13: 1006860.16）Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229-361. 1）Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin 2020; 70: 86-104. 2）Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with Nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 2018; 4: 374-8. 3）Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol 2018; 19: 1579-89. 4）Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, et al. Immune checkpoint inhibitor cardiotoxicity: Understanding basic mechanisms and clinical characteristics and finding a cure. Annu Rev Pharmacol Toxicol 2021; 61: 113-34. 5）Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018; 71: 1755-64. 6）Spallarossa P, Tini G, Sarocchi M, Arboscello E, Grossi F, Queirolo P, et al. Identification and management of immune checkpoint inhibitor-related myocarditis: Use troponin wisely. J Clin Oncol 2019; 37: 2201-5. 7）Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019; 115: 854-68. 8）Lundberg S, Lee SI. A unified approach to interpreting model predictions. arXiv 2017; : 1705.07874. 9）Wallace BC, Small K, Brodley CE, Trikalinos TA. Class imbalance, redux. Proc IEEE Int Conf Data Mining 2011; : 754-63.医療情報を活用した免疫療法誘発心筋炎予測デバイスの日米共同開発185
元のページ ../index.html#201